JP2021534114A - 併用療法 - Google Patents
併用療法 Download PDFInfo
- Publication number
- JP2021534114A JP2021534114A JP2021506715A JP2021506715A JP2021534114A JP 2021534114 A JP2021534114 A JP 2021534114A JP 2021506715 A JP2021506715 A JP 2021506715A JP 2021506715 A JP2021506715 A JP 2021506715A JP 2021534114 A JP2021534114 A JP 2021534114A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- formula
- alkyl
- prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)(Cc(cccc1)c1N1CCN(C)CC1)Nc1nc(N2CCOCC2)nc(-[n]2c(cccc3)c3nc2[*+])n1 Chemical compound CC(C)(Cc(cccc1)c1N1CCN(C)CC1)Nc1nc(N2CCOCC2)nc(-[n]2c(cccc3)c3nc2[*+])n1 0.000 description 6
- KSTNMVITYGIIAS-UHFFFAOYSA-N CC(C)(Cc(cccc1)c1-c1c[nH]nc1)Nc1nc(N2CCNCC2)nc(-[n]2c3ccccc3nc2C)n1 Chemical compound CC(C)(Cc(cccc1)c1-c1c[nH]nc1)Nc1nc(N2CCNCC2)nc(-[n]2c3ccccc3nc2C)n1 KSTNMVITYGIIAS-UHFFFAOYSA-N 0.000 description 1
- BHRWXTSCAKKIHO-UHFFFAOYSA-N CCN(CC1)CCC1c1c(CC(C)(C)N)cccc1 Chemical compound CCN(CC1)CCC1c1c(CC(C)(C)N)cccc1 BHRWXTSCAKKIHO-UHFFFAOYSA-N 0.000 description 1
- PPPQVKWLCVSFCW-OCCSQVGLSA-N CN(CC1)[C@@H](CN)[C@@H]1c(c(O)cc(O)c12)c1OC(c(ccc(C(F)(F)F)c1)c1Cl)=CC2=O Chemical compound CN(CC1)[C@@H](CN)[C@@H]1c(c(O)cc(O)c12)c1OC(c(ccc(C(F)(F)F)c1)c1Cl)=CC2=O PPPQVKWLCVSFCW-OCCSQVGLSA-N 0.000 description 1
- MJUNUDXRGBOYTG-DOMZBBRYSA-N CN(CC1)[C@@H](CO)[C@@H]1c(c(O)cc(O)c12)c1OC(c(ccc(C(F)(F)F)c1)c1Cl)=CC2=N Chemical compound CN(CC1)[C@@H](CO)[C@@H]1c(c(O)cc(O)c12)c1OC(c(ccc(C(F)(F)F)c1)c1Cl)=CC2=N MJUNUDXRGBOYTG-DOMZBBRYSA-N 0.000 description 1
- KRDDKBBKPVQIRM-UHFFFAOYSA-N ICc1nc2ccccc2[n]1-c1n[nH]c(N2CCOCC2)n1 Chemical compound ICc1nc2ccccc2[n]1-c1n[nH]c(N2CCOCC2)n1 KRDDKBBKPVQIRM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862718925P | 2018-08-14 | 2018-08-14 | |
| US62/718,925 | 2018-08-14 | ||
| PCT/US2019/046405 WO2020036995A1 (en) | 2018-08-14 | 2019-08-13 | Combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021534114A true JP2021534114A (ja) | 2021-12-09 |
| JPWO2020036995A5 JPWO2020036995A5 (https=) | 2022-08-19 |
| JP2021534114A5 JP2021534114A5 (https=) | 2022-08-19 |
Family
ID=69525833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021506715A Pending JP2021534114A (ja) | 2018-08-14 | 2019-08-13 | 併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210161909A1 (https=) |
| JP (1) | JP2021534114A (https=) |
| CN (1) | CN112839651A (https=) |
| AU (1) | AU2019322858A1 (https=) |
| EA (1) | EA202190360A1 (https=) |
| IL (1) | IL280729A (https=) |
| MX (1) | MX2021001764A (https=) |
| TW (1) | TW202021592A (https=) |
| WO (1) | WO2020036995A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11304953B2 (en) | 2017-05-23 | 2022-04-19 | Mei Pharma, Inc. | Combination therapy |
| AU2023228576A1 (en) * | 2022-03-01 | 2024-09-26 | Mei Pharma, Inc. | Combination therapy of pi3k inhibitor and pd-1 inhibitor |
| CN118949002A (zh) * | 2024-10-15 | 2024-11-15 | 杭州阿克索生物科技有限责任公司 | 一种宫颈癌细胞抑制组合物及其制备方法和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014509647A (ja) * | 2011-03-28 | 2014-04-21 | メイ プハルマ，インコーポレーテッド | （α−置換アラルキルアミノ及びヘテロアリールアルキルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、それらを含む医薬組成物、並びに増殖性疾患の治療で使用するためのこれらの化合物 |
| WO2017172826A1 (en) * | 2016-03-28 | 2017-10-05 | Presage Biosciences, Inc. | Pharmaceutical combinations for the treatment of cancer |
| WO2018053437A1 (en) * | 2016-09-19 | 2018-03-22 | Mei Pharma, Inc. | Combination therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563596B2 (en) * | 2006-06-21 | 2013-10-22 | Piramal Enterprises Limited | Enantiomerically pure compounds for the treatment of proliferative disorders |
| WO2014055647A1 (en) * | 2012-10-03 | 2014-04-10 | Mei Pharma, Inc. | (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases |
| TW201618773A (zh) * | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物 |
| US11304953B2 (en) * | 2017-05-23 | 2022-04-19 | Mei Pharma, Inc. | Combination therapy |
| KR20200041358A (ko) * | 2017-08-14 | 2020-04-21 | 메이 파마, 아이엔씨. | 병용 요법 |
-
2019
- 2019-08-13 US US17/268,049 patent/US20210161909A1/en not_active Abandoned
- 2019-08-13 WO PCT/US2019/046405 patent/WO2020036995A1/en not_active Ceased
- 2019-08-13 JP JP2021506715A patent/JP2021534114A/ja active Pending
- 2019-08-13 MX MX2021001764A patent/MX2021001764A/es unknown
- 2019-08-13 EA EA202190360A patent/EA202190360A1/ru unknown
- 2019-08-13 AU AU2019322858A patent/AU2019322858A1/en not_active Abandoned
- 2019-08-13 CN CN201980067618.0A patent/CN112839651A/zh active Pending
- 2019-08-14 TW TW108128842A patent/TW202021592A/zh unknown
-
2021
- 2021-02-08 IL IL280729A patent/IL280729A/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014509647A (ja) * | 2011-03-28 | 2014-04-21 | メイ プハルマ，インコーポレーテッド | （α−置換アラルキルアミノ及びヘテロアリールアルキルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、それらを含む医薬組成物、並びに増殖性疾患の治療で使用するためのこれらの化合物 |
| WO2017172826A1 (en) * | 2016-03-28 | 2017-10-05 | Presage Biosciences, Inc. | Pharmaceutical combinations for the treatment of cancer |
| WO2018053437A1 (en) * | 2016-09-19 | 2018-03-22 | Mei Pharma, Inc. | Combination therapy |
Non-Patent Citations (1)
| Title |
|---|
| 水島裕, 今日の治療薬（2003年版）, vol. 第25版, JPN6020025586, 15 February 2003 (2003-02-15), pages 149, ISSN: 0005037457 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021001764A (es) | 2021-04-19 |
| IL280729A (en) | 2021-03-25 |
| WO2020036995A1 (en) | 2020-02-20 |
| CN112839651A (zh) | 2021-05-25 |
| US20210161909A1 (en) | 2021-06-03 |
| AU2019322858A1 (en) | 2021-04-01 |
| EA202190360A1 (ru) | 2021-07-15 |
| TW202021592A (zh) | 2020-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6779870B2 (ja) | 抗増殖性化合物及びその使用方法 | |
| JP2021517116A (ja) | 併用療法 | |
| KR102868758B1 (ko) | Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클 | |
| JP2023001404A (ja) | 併用療法 | |
| TW202120486A (zh) | 新穎化合物 | |
| JP2020531414A (ja) | 併用療法 | |
| JP2023022081A (ja) | 併用療法 | |
| JP2021534114A (ja) | 併用療法 | |
| TW202038945A (zh) | 組合療法 | |
| US20210299134A1 (en) | Treatment of b cell malignancies | |
| WO2024147972A2 (en) | Dna polymerase theta inhibitors containing non-saturated 5-membered heterocyclic rings and use thereof | |
| EA040851B1 (ru) | Комбинированная терапия |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210625 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220810 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220810 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20220816 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220926 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221223 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230227 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230417 |